Abstract
Purpose
Treating glioblastoma through the simultaneous inhibition of multiple transduction pathways may prove more effective than single-pathway inhibition. We evaluated the safety, biologic activity, and pharmacokinetic profile of oral AEE788, a selective inhibitor of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), plus oral RAD001, a mammalian target of rapamycin inhibitor, in glioblastoma patients.
Methods
This phase IB/II, open-label, multicenter, 2-arm, dose-escalation study enrolled adult glioblastoma patients at first or second recurrence/relapse. Primary objective was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of AEE788 combined with RAD001. Secondary objectives included determining the safety/tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of the combination.
Results
Sixteen patients were enrolled (AEE788 200 mg/day + RAD001 5 mg/day, 2 patients; AEE788 150 mg/day + RAD001 5 mg every other day [qod], 14); all patients discontinued the study most commonly because of disease progression. Four patients experienced DLT (AEE788 200 mg/day + RAD001 5 mg/day, 1 patient; AEE788 150 mg/day + RAD001 5 mg qod, 3). Both patients receiving AEE788 (200 mg/day) plus RAD001 (5 mg/day) experienced clinically significant thrombocytopenia requiring a dose reduction/interruption. AEE788 appeared to inhibit the metabolism of RAD001. The study was terminated prematurely before an MTD was determined because of safety findings in other studies evaluating AEE788 monotherapy.
Conclusions
The coadministration of AEE788 and RAD001 in glioblastoma patients caused a clinically significant thrombocytopenia and a higher-than-expected RAD001 area under the curve concentration when dosed at 200 and 5 mg/day, respectively. After a dose reduction to AEE788 (150 mg/day) and RAD001 (5 mg qod), the combination appeared to be better tolerated.
References
Humphrey PA, Wong AJ, Vogelstein B et al (1998) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48:2231–2238
Frederick L, Wang XY, Eley G et al (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387
Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319
Stockhammer G, Obwegeser A, Kostron H et al (2000) Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol 100:101–105
Fan QW, Specht KM, Zhang C et al (2003) Combinatorial efficacy achieved through two-point blockade within a signaling pathway-A chemical genetic approach. Cancer Res 63:8930–8938
She QB, Solit D, Basso A et al (2003) Resistance to gefitinib in PTEN-null HER overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9:4340–4346
Bianco R, Shin I, Ritter CA et al (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812–2822
Podsypanina K, Lee RT, Politis C et al (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten ± mice. Proc Natl Acad Sci USA 98:10320–10325
Goudar RK, Shi Q, Hjelmeland MD et al (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma multiforme tumor growth inhibition. Mol Cancer Ther 4:101–112
Nakachi I, Naoki K, Soejima K et al (2010) The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib-resistant lung cancer cell line through c-Met inhibition. Mol Cancer Res 8:1142–1151
Nashan B (2002) Review of the proliferation inhibitor everolimus. Exp Opin Investig Drugs 11:1845–1857
O’Donnell A, Faivre S, Burris HA III et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588–1595
Thall PF, Millikan RE, Mueller P et al (2003) Dose-finding with two agents in phase I oncology trials. Biometrics 59:487–496
Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 17:1103–1120
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Hahn GJ, Meeker WQ (1991) Statistical intervals: a guide for practioners. Wiley, New York
Amato RJ, Jac J, Giessinger S et al (2009) A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115:2438–2446
Wolpin BM, Hezel AF, Abrams T et al (2008) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27:193–198
Patnaik A, Ricart A, Cooper J et al. (2007) A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multitargeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J Clin Oncol 25(suppl 18):141 s. abstract 3512
Chang SM, Kuhn J, Lamborn T et al. (2009) Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG)(NABTC 04–02). J Clin Oncol 27(suppl 15):88 s. abstract 2004
Patel PH, Senico PL, Curiel RE, Motzer RJ (2009) Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 7:24–27
Acknowledgments
We are indebted to the patients who participated in this study and study coordinators. We thank Syntaxx Communications, Inc. for assistance with manuscript development and editing. Research support by Novartis Pharmaceuticals Corporation, East Hanover, NJ.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reardon, D.A., Cloughesy, T., Rich, J. et al. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol 69, 281–287 (2012). https://doi.org/10.1007/s00280-011-1754-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-011-1754-1